MiNK Therapeutics, Inc.INKTNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-37.84%
↓ 428% below average
Average (22q)
11.54%
Historical baseline
Range
High:293.20%
Low:-70.62%
Volatility
3152.4%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -37.84% |
| Q2 2025 | 45.75% |
| Q1 2025 | -10.25% |
| Q4 2024 | 160.06% |
| Q3 2024 | -70.62% |
| Q2 2024 | -27.83% |
| Q1 2024 | -23.00% |
| Q4 2023 | -3.40% |
| Q3 2023 | -24.81% |
| Q2 2023 | 8.70% |
| Q1 2023 | -27.85% |
| Q4 2022 | -5.49% |
| Q3 2022 | 4.66% |
| Q2 2022 | 11.35% |
| Q1 2022 | 33.57% |
| Q4 2021 | 18.50% |
| Q3 2021 | -6.99% |
| Q2 2021 | 15.72% |
| Q1 2021 | 293.20% |
| Q4 2020 | -68.54% |
| Q3 2020 | -19.45% |
| Q2 2020 | -0.00% |
| Q1 2020 | 0.00% |